Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.

  title={Waldenstr{\"o}m macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.},
  author={Morie A Gertz},
  journal={American journal of hematology},
  volume={87 5},
DISEASE OVERVIEW Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy. DIAGNOSIS Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. RISK STRATIFICATION Age, hemoglobin level, platelet count, β(2) microglobulin, and monoclonal IgM concentrations are characteristics… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 16 extracted citations

Waldenström’s Macroglobulinemia

Springer International Publishing • 2017


Publications referenced by this paper.
Showing 1-10 of 82 references

Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treatment in patients with indolent lymphomas and Waldenström’s macroglobulinemia [abstract

MJ Rummel, N Niederle, U von Grunhagen
The Sixth International Workshop on Waldenström’s Macroglobulinemia, • 2010
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…